
Simplification of the therapeutic regimen to enable compliance is the primary rationale for using a fixed-combination product in the management of glaucoma, but IOP-lowering efficacy along with safety and tolerability cannot be overlooked.

Simplification of the therapeutic regimen to enable compliance is the primary rationale for using a fixed-combination product in the management of glaucoma, but IOP-lowering efficacy along with safety and tolerability cannot be overlooked.

A portfolio of diagnostic, therapeutic, and data management tools for glaucoma can improve clinical assessment and progression analysis.

Alcon Laboratories announced Sept. 21 that the FDA approved travoprost ophthalmic solution 0.004% formulated with a proprietary ionic-buffered preservative system for first-line treatment to reduce elevated IOP in patients with ocular hypertension or open-angle glaucoma.

The newly expanded $132 million Kellogg Eye Center at the University of Michigan, Ann Arbor, boasts 230,000 square feet of clinical and research space across eight floors that house clinics, six operating rooms, research space, and faculty offices.

Sunwear protects eye health, enhances vision in bright sunlight, and contributes to the bottom line.

Disability from symptoms of dry eye disease among patients using latanoprost 0.005% may be significantly improved by switching to a benzalkonium chloride-free formulation of travoprost 0.004%.

Alpha adrenoceptor agonist therapy using brimonidine tartrate 0.1% with a preservative has a wide spectrum of uses in the management of ocular hypertension and glaucoma.

A dexamethasone 0.7 mg intravitreal implant now is approved for treatment of non-infectious uveitis affecting the posterior segment of the eye.

Letter addresses 2010 Ophthalmology Times Best Programs survey.

Understanding of the physiology of aqueous outflow resistance through the conventional outflow pathway should help to identify new therapeutic targets for IOP lowering and may lead to novel modalities for glaucoma therapy, according to one expert.

Remembering the rules of the road can help clinic managers and administrators who want to keep their practice on the road with minimal breakdowns.

Selective laser trabeculoplasty is a safe and effective first-line procedure for glaucoma that works as well as the strongest anti-glaucoma medication.

Under the theme of "Visionary Genomics," researchers and clinicians will gather at the 2011 annual meeting of the Association for Research in Vision and Ophthalmology in May in Fort Lauderdale, FL, to explore how genomic technology is leading to new understanding of vision health, disease and treatment.

Optos has entered into an agreement with Accutome Inc. to distribute three of its medical devices in North America and targeted European markets starting in November.

A potential advance in the fight against blindness is the development of an experimental oral synthetic retinoid compound to treat two subtypes of Leber's congenital amaurosis.

Compared with standard 2.75-mm coaxial small-incision cataract surgery, eyes treated with biaxial microincision cataract surgery sustained less trauma due to lower amounts of energy and faster visual rehabilitation.

Findings from bench model studies measuring higher-order aberrations and near, intermediate, and distance image quality of presbyopia-correcting IOLs provide further insight on the clinical performance of the available implants.

Two distinct regions of the cornea have key anatomic, physiologic, and pathologic differences.

The approval of bimatoprost ophthalmic solution 0.01% expands medical treatment options for glaucoma and could improve adherence.

Multiple features of a new modular platform for non-contact retinal visualization make it a welcome addition for vitreoretinal surgeons.

This physician's belief is that physicians tend to think of everyone as being different, because it's a physician's duty to do so.

Wavefront-guided LASIK and wavefront-optimized LASIK both produced similar results when compared head to head in two studies.

Application of a proprietary femtosecond laser to perform lens liquefaction, capsulorhexis, and corneal incisions is safe, effective, and offers potential advantages that suggest this technology will usher in a new era in cataract surgery.

The results of the 2010 Ophthalmology Times Best Programs survey show very few differences from last year despite advances and growth within ophthalmology departments across the United States.

Delivering health care in rural areas often can be challenging for members of the medical community.

Data from the Confocal Scanning Laser Ophthalmoscopy Ancillary Study show that ther eare changes in optic disc topography in eyes with ocular hypertension, whether or not there is progression to primary open-angle glaucoma.

Administration of the shingles vaccine in patients with active acute ocular zoster infection is not indicated, and use of the vaccine in a patient with active interstitial keratitis actually may worsen the disease.

The 2010 joint meeting of the American Academy of Ophthalmology and the Middle East Africa Council of Ophthalmology was to convene in Chicago from Oct. 16 to 19.

Preliminary results of a phase I/II study suggest that targeting complement factor 5 in combination with anti-vascular endothelial growth factor therapy may have a role for improving visual acuity outcomes to eyes with exudative age-related macular degeneration.

Allergan, the $3 billion multi-specialty health-care company, boasts one of those classic start-up stories that businesses today dream about: Chemist Stanley Bly had an idea for a novel anti-allergy nose drop, so he approached his friend Gavin S. Herbert Sr., who owned a pharmacy and nursed an entrepreneurial spirit.